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(p0.0003). Burden was recorded among caregivers of patients with (at inclusion)
euthymia (43.8  13.1; n329), mania (47.7  13.6; n41), hypomania (51.6  12.7;
n44), depression (49.9  14.4; n137), or mixed disease status (50.2  9.5; n20).
CONCLUSIONS: This ongoing study provides multinational perspectives on the
high burden experienced by caregivers of individuals with BD-I and BD-II in every-
day clinical practice settings. Study funded byAstraZeneca; Clinical Trials Registry:
NCT01062607.
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OBJECTIVES: As data is limited, to determine national estimates and characteris-
tics of Alzheimer’s disease and senile dementia (ADSD) visits in the United States
(US) ambulatory setting. METHODS: Through a retrospective analysis of the 10-
year (1998-2007) physician-office visit data of National Ambulatory Medical Care
Survey, we calculated weighted national estimates and percentages of ADSD
visits made by patients aged 40 years and older with relevant ICD-9CM codes
(290.xx, 294.xx, 331.xx). In multivariate logistic regression we analyzed the charac-
teristics associated with anti-dementia drug mention at ADSD visits. RESULTS:
Of an estimated 6.5million adult ambulatory care visits (5 visits per 1000 people) for
ADSD, 52%, 25%, 20%, 14%, and 11%, mentioned an antidementia (memantine,
cholinesterase inhibitor, or donepezil/rivastigmine/gallantamine), anticholinergic,
antidepressant, antipsychotic, and antianxiety drug respectively. Patients with
ADSD visits were predominantly 75-84 year olds (53%), white (89%), female (63%),
living in metropolitan statistical area (81%), South (30%) and Northeast (28%), on
Medicare (73%), seeing a freestanding private practice physician (61%) or a neurol-
ogist (32%), established patient (88%), and reported hypertension (12%). In multi-
variate analyses controlling for gender, type of dementia, comorbidity, and visit-
year, any versus no anti-dementia drug mention was significantly less likely at
visits by other versus white-race patients (adjusted odds ratio [OR] is 0.44,95%CI:
0.42-0.46), new versus established patients (OR0.38;95%CI:0.37–0.39), by those on
self-pay versus private-insurance (OR0.63;95%CI:0.56–0.70), and in South
(OR0.43;95%CI:0.41–0.44) and West (OR0.41;95%CI:0.40–0.43) versus those in
Northeast (all P 0.0001). CONCLUSIONS: About 50% and 25% of ADSD visits
mentioned an anti-dementia drug and other drugs, respectively. New patients,
those of other races, on self-pay and living in South or West of the US were less
likely to receive an anti-dementia drug. Study findings’ suggest deficiencies in
access and quality of dementia care in the USwarranting the attention of providers
and payers and need further study.
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INTRODUCTION Although benzodiazepines are primarily considered anxiolytics,
some have other indications such as seizures, insomnia, alcohol withdrawal, and
tardive dyskinesia. They are also commonly abused medications, especially the
brandnameproducts, alone and in combinationwith other drugs (e.g.methadone).
They are classified, on the basis of their half lives, into short-, intermediate- and
long-acting agents. The side effects of falling and fractures cause benzodiazepines
to be unattractive for elderly patients. OBJECTIVES: To describe trends in the uti-
lization of, spending on, and average per-prescription spending on benzodiaz-
epines, individually, stratified by half life, and overall, for the U.S. Medicaid pro-
grams over the past two decades.METHODS: A retrospective, descriptive analysis
was performed using the national Medicaid pharmacy claims database, which has
information on outpatient prescription claims. Quarterly prescription counts and
reimbursement amountswere calculated for each of the benzodiazepines (branded
or generic) reimbursed by Medicaid. Average per-prescription spending was found
by dividing reimbursement by the number of prescriptions. RESULTS: Prescrip-
tions for benzodiazepines among Medicaid beneficiaries increased from 6.15 mil-
lion in 1991 to 16.70 million in 2009. Expenditures rose from $108.75 million to
$165.79 million over the same time period, implying an average per-prescription
price of approximately $10 in 2009. Whereas utilization of long-acting agents re-
mained relatively constant at 1.79 million prescriptions per year, prescriptions for
short-acting and intermediate-acting drugs rose from 1.74 million to 4.94 million,
and from 2.82 million to 9.91 million, respectively. Prescriptions for flurazepam
have fallen steadily from 439,106 in 1991 to 45,754 in 2009. CONCLUSIONS: Spend-
ing on benzodiazepines represents  1% of Medicaid’s spending on outpatient
drugs. Moreover, due to generic entry for some of the drugs, the percentage rise in
spending on benzodiazepines since 1991 (52.5%) was less than the general rate of
inflation (57.5%). By its policy of reimbursing for generic, rather than branded,
prescriptions, Medicaid reduces the opportunity for abuse.
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OBJECTIVES: The U.S. Food and Drug Administration’s decision to mandate a black-
boxwarning on antidepressants indicating that they are associatedwith an increased
risk of suicidal behavior in children and young adults remains controversial. We
aimed to quantify the tradeoffs of alternative strategies in treating pediatric major
depressive disorder (MDD) with respect to clinical benefit and risk of fatal and non-
fatal suicidal behavior over a five-year time horizon. METHODS: We developed a
disease simulationmodel integrating epidemiological and clinical data from the pub-
lished literature in order to simulate the effect of three treatment strategies (i.e., Se-
lective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and a
combination of SSRIs andCBT) on aU.S. population of children and young adultswith
MDD. We explored the implications of different scenarios of data extrapolation be-
yond the time horizon of existing data and of uncertain assumptions about suicide
attempt risks and patients’ response to treatment. Main outcome measures were
symptom-free weeks, suicide attempts, and suicide deaths. RESULTS: In a cohort of
1,000,000 simulated children and young adults, there were more than twice as many
suicide deaths among those started on SSRIs (1291), compared to those started onCBT
(506) or combination treatment (621) over the first 36 weeks of treatment. Over a
five-year time horizon, this hierarchy of suicide risk persisted, even under assump-
tions most favorable to SSRIs. With respect to symptom-free weeks, combination
treatmentwas superior to both SSRIs and CBT alone, but this differencewasmarginal
over a five-year time horizon. CONCLUSIONS: Considering the risk-benefit profile
over a five-year period, CBT appears to offer a safer profile with respect to suicide
deaths and attempts than combination treatment or SSRIs alone. While combination
treatment maximizes symptom-free weeks, the additional benefit over the five-year
time horizon is modest and must be weighed against the clinically meaningful in-
crease in fatal suicides.
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COMPARISON OF THE RISPERIDONE EQUIVALENT DOSES FOR THE 9 MOST
FREQUENT TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN PATIENTS
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ACTUAL DOSAGES PRESCRIBED IN A LARGE NATIONAL DATABASE
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OBJECTIVES: Physicians often make dosage decisions based on experience and
heuristic factors in addition to the product label. This makes it difficult for econo-
mists to compare the “real world” costs and benefits of alternative therapeutic
choices. We compare a published methodology for calculating therapeutic dose
equivalence based on approved labeling for varous antipsychotics prescribed for
schizophrenia with actual prescription data in that population. METHODS: The
sample consisted of a proportional selection of patients that derived from a popu-
lation of patients of all ages, across all payers, and in all regions of the United
States. The information included NDC code sets, quantity, and day of supply and
was aggregated from pharmaceutical prescriptions files. The frequency distribu-
tion measured the top antipsychotic medications in patients diagnosed with
schizophrenia. The therapeutic dose equivalence was determined using themeth-
odology of Woods (2003) as the comparator. RESULTS: A total of 324,724 patients
with a diagnosis of schizophrenia were included in the study. Doses equivalent to
1mg/day of Risperidonewere 86.17mg/day of Quetiapine, 5.09mg/day of Olanzap-
ine, 5.25 mg/day of Aripiprazole, 92.28 mg/day of Clozapine, and 33.74 mg/day of
Ziprasidone. CONCLUSIONS:With the ever-increasing array of differntially-dosed
medications available, it is imperative for physicians and outcomes researchers to
utilize estimation of therapeutic dose equivalence that reflects actual practice pat-
terns so that informed decisions can be made evaluating the cost and cost-effec-
tiveness of various therapeutic choice. Our study enables pharmacoeconomic
comparisons among antispychotics not only according to label-approved dosages,
but also real-world dosing patterns.
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EFFECT OF PRESCRIPTION MONITORING PROGRAMS (PMP’S) ON OPIOID
OVERDOSE ADMISSION
Painter JT
University of Kentucky, Lexington, KY, USA
OBJECTIVES: Over the past three decades the concept of prescription monitoring
programs (PMPs) has developed immensely, however little evidence regarding
their effectiveness has been collected. This study focuses on simple difference-in-
difference evaluations, comparing the implementation effect of a PMP in Tennes-
see with Kentucky, which has a well-established PMP, andMissouri, which has not
to-date enacted legislation to develop a PMP. The effect of interest is opioid over-
dose hospital admission.METHODS: The present study examines a simple differ-
ence-in-difference model of a natural experiment caused by the staggered imple-
mentation of prescription monitoring programs in Kentucky, Missouri, and
Tennessee. We implement a pre-post design with the primary outcome of interest
being hospital admission due to opioid overdose. For this evaluation we use all
claims from Kentucky, Missouri, and Tennessee in the HCUP-NIS data from 2006
and 2008. The data is separated according to whether the hospital admission was
due to opioid overdose. Four models are examined: main effects, individual fixed
effects, and the full model, which takes into account both year and state fixed
effects and shows the true effect of the Tennessee implementation. Although the
findings in the Tennesseemodels trend positively, there are no significant findings
in the full model. RESULTS:We look at various models, including fixed effects for
state and year, but no consistently significant effect is seen. Despite no statistically
significant findings, coefficients do trend in expected directions suggesting a sound
model. CONCLUSIONS: There are multiple possible reasons for the lack of signifi-
cant findings, including several study limitations. Despite the limitations, it can be
said that the Controlled Substance Abuse Database Program in Tennessee has no
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significant effect on opioid overdose hospital admission. Given the lack of infor-
mation in this field of research, especiallywhen considering clinical outcomes, this
is an important addition to the literature.
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OBJECTIVES: We estimate the rates and types of depression treatment among
individuals with multimorbidity and depression and compare these to individuals
without multimorbidity. We also examine the relationship between multimorbid-
ity and depression treatment after controlling for demographic, socio-economic,
access to care, life-style factors and the number of visits to either office-based
provider or outpatient hospital clinics.METHODS:We did cross-sectional analysis
of 1,376 individuals of age above 21, with depression and at least one chronic
physical condition in the following clusters: cardio-metabolic (diabetes or heart
disease or hypertension), respiratory (chronic obstructive pulmonary disease or
asthma) and musculoskeletal (osteoarthritis or rheumatoid arthritis or osteoporo-
sis) from the 2007 Medical Expenditure Panel Survey (MEPS). Chi-square tests, lo-
gistic regression and multinomial logistic regressions were performed to analyze
the rates and types of depression treatment among various chronic clusters. All
analysis accounted for the MEPS survey design. RESULTS: Of our study sample,
56.2% reported use of antidepressants, 21.4% had psychotherapy with or without
antidepressants and 22.4% reported no depression treatment at all. The individuals
in “respiratory only” and “musculoskeletal only” were less likely to be on antide-
pressants and those in “respiratory only” group were less likely to opt for psycho-
therapy with or without antidepressants in the unadjusted model. After adjusting
for all demographic, socio-economic, access to care, life-style factors and number
of visits, only those in “respiratory only” group were less likely to be treated with
psychotherapy with or without antidepressants. CONCLUSIONS: Presence of mul-
timorbidity is not a barrier to depression treatment suggesting that competing
demands due to multimorbidity may not affect depression treatment. Also the
individuals in ‘respiratory only’ group were less likely to be on psychotherapy.
Therefore, further studies are needed to explore the relationship between psycho-
therapy for depression treatment and respiratory conditions.
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OBJECTIVES: The objective of this study was to identify the national rates of co-
prescribing cholinesterase inhibitors with anticholinergic urinary incontinence
medications using the National Ambulatory Medical Care Survey (NAMCS) and the
National Hospital Ambulatory Medical Care Survey (NHAMCS). Anticholinergic
classes of medications have a mechanism of action that opposes the cholinest-
erase inhibitors; therefore, when taken concomitantly the effectiveness of these
medications potentially decreases. The objective of this study was to describe the
concomitant prescribing of cholinesterase inhibitors and anticholinergic drugs in-
dicated for urinary incontinence. METHODS: This study was a retrospective, ob-
servational, cross-sectional, database analysis using data from the 2006-2008
NAMCS and NHAMCS outpatient departments. Patient visits that included a pre-
scription for a cholinesterase inhibitor alone or combined with an anticholinergic
medication approved for urinary incontinence were analyzed. The data was
weighted to produce national estimates and analyzed using descriptive statistics.
RESULTS: Over the 3 year period there were 13,345,926 visits including cholinest-
erase inhibitors. Of the visits including a cholinesterase inhibitor, 5.5% (n737,064)
also included a prescription of an anticholinergic urinary incontinencemedication.
The most commonly prescribed cholinesterase inhibitor was donepezil
(n11,173,472; 83.5%). The majority of patient visits that included the prescription
of both a cholinesterase inhibitor and an anticholinergic medication weremade by
patients over 80 years of age (n404,359; 54.9%). The most common physician
specialty to prescribe both cholinesterase inhibitors alone (n6,587,573; 49.2%) and
the combination with an anticholinergic medication (n333,135; 45.2%) were fam-
ily practitioners and general practice/internal medicine. Urologists and obstetri-
cians/gynecologists represented the prescribing physicians in 16.8% (n123,465) of
visits with combination therapy, whereas they accounted for 3.1% (n415,818) of
the cholinesterase inhibitor prescribing. CONCLUSIONS: Cholinesterase inhibitors
and anticholinergic urinary incontinence medications were inappropriately pre-
scribed together. Educating health care providers and patients about this potential
interaction can optimize drug therapy for patients on cholinesterase inhibitors.
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OBJECTIVES: Pharmacologic treatment has a major role in the management of
depression, but concerns about the safety of antidepressants, and in particular the
increased risk of suicide, have prompted FDA blackbox warnings. The objective of
this analysis was to describe the trends in utilization of prescription antidepres-
sants over the past decade and interpret these in the context of FDA actions over
that same time period.METHODS: National prescription data were obtained from
IMS XponentTM database for the period January 1999-December 2009 (inclusive).
Total prescription counts were determined for TCAs, SSRIs, and SNRIs. The FDA
website was reviewed to identify the dates of new warnings or safety-related la-
beling changes, including major warnings in 2004 and 2007. RESULTS: Total pre-
scriptions for antidepressants grew from10.9million in 1999 to 19.3million in 2009,
with only a temporary decline occurring in 2004-2005 which corresponds with the
initial FDAwarning.While the warnings applied to all antidepressants, differences
in utilization patterns between classes are apparent. TCAs declined in use, while
both SNRI and SSRI prescriptions increased over the decade, although SNRI utili-
zation leveled-off after the 2007 expansion of the FDA blackbox warning that ap-
plied to young adults (18-24). CONCLUSIONS: Despite continuing expansion of the
scope of the FDA blackbox warnings, overall antidepressant utilization increased
over the decade, although the rate of increase appears to have slowed in the past
two years.
PMH69
HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS WITH BIPOLAR
DISORDER: RETROSPECTIVE DATA FROM A LARGE MULTINATIONAL
LONGITUDINAL STUDY (WAVE-BD)
Vieta E1, Figueira ML2, Bellivier F3, Souery D4, Blasco-Colmenares E5, Langosch JM6,
Medina E7
1Bipolar Disorders Programme, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM,
Barcelona, Spain, 2Hospital Santa Maria, Faculty of Medicine, University of Lisbon, Lisboa,
Portugal, 3Hôpital Henri Mondor, Créteil cedex, France, 4Centre Européen de Psychologie
Médicale, Psy-Pluriel, Brussels, Belgium, 5Welch Center for Prevention, Epidemiology, and Clinical
Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 6Bethanien
Hospital for Psychiatry, Psychosomatics, and Psychotherapy, Greifswald, Germany, 7AstraZeneca
Pharmaceuticals LP, Madrid, Spain
OBJECTIVES:WAVE-bd (WideAmbispectiVE study of the clinicalmanagement and
burden of bipolar disorder [BD]) is ongoing to address limitations of longitudinal BD
studies to date. As part of this study, healthcare utilization among patientswith BD
was assessed in amultinational BD patient cohort.METHODS:Multinational, mul-
ticenter, non-interventional, longitudinal study of patients diagnosedwith BDwith
1 mood event in the preceding 12 months (retrospective data collection from
indexmood event to enrollment, followed by aminimum of 9months’ prospective
follow-up). Site and patient selection provided a representative sample of patients
cared for in each country, including medical health centers, clinics, private set-
tings, hospitals or specialized units.RESULTS: In total, 2880 patients (mean age 46.5
years [SD: 13.3]; 62% female) were recruited from 10 countries. During the retro-
spective period, 94.3% of patients received usual treatment for BD, which included
atypical antipsychotics, anticonvulsants, antidepressants, lithium and electrocon-
vulsive therapy. Psychiatric visits were the most frequently used healthcare re-
source, with 8.62 8.25 and 0.96 3.16 (mean SD) programmed and spontaneous
visits per patient-year, respectively. There was a mean of 1.46  5.67 visits to the
psychologist per patient-year. Hospitalization rates since diagnosis and index
event were 0.45 0.83 and 0.34 1.14/patient-year, respectively (time [years] since
diagnosis was 11.13  10.39 overall; BD-I: 11.97  10.46; BD-II: 9.46  9.95). There
were 0.49 4.54, 0.74 4.31 and 0.14 0.68 group therapy, general practitioner and
emergency department visits per patient-year since the index event, respectively.
Overall, there were 85  370 suicide attempts per 1000 patient-year.
CONCLUSIONS: Resource use in this population with BD was considerable, indi-
cating the high burden associated with BD in healthcare systems across different
countries and healthcare settings, representative of everyday clinical practice.
Study funded by AstraZeneca; Clinical Trials Registry: NCT01062607.
PMH70
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OBJECTIVES: Prescription medications are a cornerstone of mental health treat-
ment. From 1993 to 2003, drug spending was responsible for 46% of the increase in
USmental health expenditures. Psychiatric drugs have also been a driver of spend-
ing on all medications, comprising 26% of Medicaid and 14% of private insurance
drug spending. This study analyzes recent trends in psychiatric prescription drug
spending. Potential drivers were evaluated: generic drug entry; prevalence of uti-
lization; benefit plan design; drug safety concerns; comparative effectiveness re-
search, and new product entry and indications. METHODS: Data were from the
Substance Abuse and Mental Health Services Administration Spending Estimates
and Thomson Reuter’s MarketScan Commercial Database for 1997 through 2008
and from IMS Health. The SAMHSA estimates use similar definitions, data, and
methods as the national health expenditure accounts produced by the CMS and are
based primarily on nationally representative databases. SAMHSA drug spending
was derived from the Medical Expenditure Panel Survey and checked against data
from IMS Health. RESULTS: From 1997 to 2001, national psychiatric medication
spending grew by more than 20% annually. Data from 2001 through 2008 show a
dramatic and steady decline in the spending growth. The average annual growth in
the users per enrollee declined from 7% to 2% from 1997-2001 to 2001-2008. The
average annual increase in costs per day declined from 8% to 2%. Days per user
declined only slightly from 3% to a 2%. A key contributor to the slower price growth
was generic entry, particularly generic antidepressants, encouraged by formulary
design. Generic medications grew from 36% to 70% of all psychiatric prescriptions
from 1997 to 2008. Drug safety concerns also contributed to the spending slow
down. Major comparative effectiveness studies did not have a large impact on
spending growth. CONCLUSIONS: Past high growth in psychiatric drug spending
arising from growth in utilization of branded medications has declined signifi-
cantly, which may have implications for access and new product investment.
A198 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
